Why the study?
What are the rates of complications and appropriate therapies following ICD generator replacement?
What are the rates of complications and appropriate therapies following ICD generator replacement?
ICD generator replacement is associated with substantial complication rates (median 4.05% major), but patients continue to receive appropriate therapies at nontrivial rates (annualized 10.52%), highlighting the need for shared decision-making.
Answers are grounded in this paper and cite their sources.
Substantial ICD replacement complications warrant cautious shared decision-making; leaves open net benefit without controlled post-replacement data.
BACKGROUND: Every 4-7 years an implantable cardioverter defibrillator (ICD) pulse generator must be replaced surgically. This procedure is not without risk. In some cases, the risk versus benefit ratio may be against replacement. We aimed to synthesize the evidence on risks, benefits, and costs related to ICD replacement. METHODS: A systematic review was conducted using electronic databases from 2000 onward. Literature screening, quality appraisal, and data extraction were independently conducted by two reviewers. Outcomes included major and minor complications, ICD therapies, and costs, which were synthesized descriptively. RESULTS: Of 1,483 citations, 17 nonrandomized studies met criteria. Median rate of major complications was 4.05% (range 0.55-7.37%) and minor complications was 3.50% (range 0.36-7.37%). Without non-ICD control groups, the true risk reduction provided by the ICD following replacement is unknown. Following ICD replacement, annualized rate of appropriate ICD therapy was 10.52% (range 2.42-75.00%). Of these, patients without therapies during their first generator life and those no longer meeting ICD criteria received appropriate therapies at nontrivial rates. CONCLUSION: Rates of complications associated with ICD replacement are substantial. No study had nonreplacement groups, hence the true risk reduction provided by the ICD following replacement is unknown. Our analysis did not identify a subgroup at low risk of therapies following replacement. Shared discussions should occur with patients about the evidence, healthcare goals, risk tolerances, and feelings about life and death trade-offs to enable high-quality decisions about ICD replacement.
No takes yet. Share an insight, caveat, or question.
Lewis et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: